UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$516.33

Market cap

$21.92B

P/E Ratio

17.63

Dividend/share

N/A

EPS

$29.28

Enterprise value

$20.64B

?
Relative Growth: Rel. Growth: 79
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 57
Relative Profitability: Rel. Profitability: 95

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to ...

Highlights
The debt has plunged by 100% YoY
The company's revenue rose by 6% YoY
The company's EPS rose by 8% YoY but it fell by 2.8% QoQ
UNITED THERAPEUTICS's net income has increased by 6% YoY but it has decreased by 3.5% QoQ
The quick ratio has declined by 29% since the previous quarter and by 18% year-on-year
The stock's P/E is 24% above its 5-year quarterly average of 14.3 and 15% above its last 4 quarters average of 15.4
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.27%
1 week
-2.2%
1 month
-7.12%
1 year
75.46%
YTD
5.97%
QTD
-4.71%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$3.17B
Gross profit
$2.74B
Operating income
$1.44B
Net income
$1.29B
Gross margin
86.6%
Net margin
40.6%
UNITED THERAPEUTICS's net income has increased by 6% YoY but it has decreased by 3.5% QoQ
The company's revenue rose by 6% YoY
The operating income has contracted by 3.8% from the previous quarter but it has grown by 2.3% YoY
The net margin has contracted by 3.1% from the previous quarter

Price vs fundamentals

How does UTHR's price correlate with its fundamentals

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
17.63
P/B
3.83
P/S
7.09
EV/EBIT
12.7
EV/EBITDA
12.04
EV/Sales
6.51
The stock's P/E is 24% above its 5-year quarterly average of 14.3 and 15% above its last 4 quarters average of 15.4
The company's EPS rose by 8% YoY but it fell by 2.8% QoQ
UTHR's price to book (P/B) is 60% higher than its 5-year quarterly average of 2.4 and 28% higher than its last 4 quarters average of 3.0
The equity has declined by 17% since the previous quarter and by 13% year-on-year
The stock's P/S is 31% above its 5-year quarterly average of 5.4 and 13% above its last 4 quarters average of 6.3
The company's revenue rose by 6% YoY

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The company's return on sales fell by 6% QoQ and by 3.9% YoY
The ROIC has contracted by 4.1% from the previous quarter and by 3.8% YoY
UNITED THERAPEUTICS's return on assets has increased by 3% YoY

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has declined by 29% since the previous quarter and by 18% year-on-year
The current ratio has contracted by 27% from the previous quarter and by 12% YoY
The debt is 100% less than the equity
UNITED THERAPEUTICS's debt to equity has shrunk by 100% YoY
The debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.